01 January 1970 0 6K Report

After a debate of several years on the robustness of commercial antibodies through multiple publications (see latest reviews in our blog https://aeonianbiotech.com/introduction-to-aeonian-rating-and-antibody-registry/), a shift towards higher quality presentation of the products in many catalogs is happening right now.

Is any of this visible to researchers in the labs at all? Do researchers, who depend on high quality antibodies from commercial sources, find it easy identifying the correct reagents from a very complex market place? Or is it just a matter of hit or miss approach?

Is molecular integrity and selectivity a concern at all?

More Jan Voskuil's questions See All
Similar questions and discussions